Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367381 | 1.00 | CTSK (0.48) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL2367189 | 1.00 | CTSK (0.48) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL14190234 | 0.94 | CTSS (0.47) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL13722720 | 0.85 | CTSS (0.44) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL7813096 | 0.83 | CTSK (0.43) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL4086808 | 0.81 | CTSS (0.44) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL47290 | 0.80 | TGFBR1 (0.52) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL318796 | 0.80 | CTSK (0.64) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL47301 | 0.80 | TGFBR1 (0.52) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL1951491 | 0.80 | CTSK (0.64) | CTSKCTSSPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7727956-B2 | Deoxonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727956-B2 | Deoxonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20080058253-A1 | Deoxononadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| US-20060264358-A1 | Acylated nonadepsipeptides II | BAYER HEALTHCARE AG (DE) | 2006-11-23 | — | — | US | disclosed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1625153-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | Bayer HealthCare AG (DE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| WO-2004099239-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTSK 393/4885CTSS 459/4885PPARA 808/4885 |
| US-20080058253-A1 | Deoxononadepsipeptides | VIP, DNPEP, NPPA | CTSK 454/4885CTSS 1183/4885PPARA 908/4885 |
| US-20060264358-A1 | Acylated nonadepsipeptides II | VIP, LYPLA2, ENPP2 | CTSK 1046/4885CTSS 1723/4885PPARA 500/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | CTSK 7/4885CTSS 3/4885PPARA 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.